Lumexa Imaging Holdings, Inc. Common Stock

Lumexa Imaging Holdings narrowed its 2026 adjusted EBITDA guidance to $235 million to $241 million while maintaining the midpoint at $238 million. The company reiterated consolidated revenue guidance of $1.045 billion to $1.097 billion and adjusted EPS guidance of $0.71 to $0.77 per share. Second quarter consolidated revenues were $264.2 million, with adjusted EBITDA of $56.4 million and adjusted EPS of $0.20. Advanced modalities grew to a record 37.4% of total volume, and the company announced a joint venture with Hospital for Special Surgery, its ninth health system joint venture.